Professor Sir Andrew Pollard, director of the Oxford Vaccine Group, has said that the UK is "going to have to live with" COVID-19, BBC News reported on Wednesday.
Prof Pollard, speaking to the Commons Science and Technology Committee, was quoted as saying that "variants and their emergence" will "continue to happen".
He added: "But in the end, we're going to have to come back to focusing on the really important public health issue, which is the hospitalisation and the death. If transmission is disconnected by vaccine immunity from the severe disease, to a large extent, then we'll need to monitor new variants, perhaps, if we need to find new vaccines and so on - but we are going to have to live with it being in our communities and transmitting."
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Zoetis announces EU approval for Portela to relieve osteoarthritis pain in cats
4basebio synthetic DNA used in Phase I/II mRNA therapy trial
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Sanofi reports data showing high-dose flu vaccine delivers superior protection for older adults
GC Biopharma granted CMO rights for Curevo Vaccine's shingles vaccine